Jazz Pharmaceuticals Plc Stock Current Ratio
| J7Z Stock | EUR 116.85 1.15 0.97% |
Jazz Pharmaceuticals plc fundamentals help investors to digest information that contributes to Jazz Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Jazz Stock. The fundamental analysis module provides a way to measure Jazz Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Jazz Pharmaceuticals stock.
Jazz |
Jazz Pharmaceuticals plc Company Current Ratio Analysis
Jazz Pharmaceuticals' Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Current Jazz Pharmaceuticals Current Ratio | 3.15 X |
Most of Jazz Pharmaceuticals' fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Jazz Pharmaceuticals plc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
| Competition |
In accordance with the recently published financial statements, Jazz Pharmaceuticals plc has a Current Ratio of 3.15 times. This is 8.25% higher than that of the Healthcare sector and 55.0% lower than that of the Biotechnology industry. The current ratio for all Germany stocks is 45.83% lower than that of the firm.
Jazz Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Jazz Pharmaceuticals' direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Jazz Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Jazz Pharmaceuticals by comparing valuation metrics of similar companies.Jazz Pharmaceuticals is currently under evaluation in current ratio category among its peers.
Jazz Fundamentals
| Return On Equity | -0.0056 | |||
| Return On Asset | 0.053 | |||
| Profit Margin | (0.01) % | |||
| Operating Margin | 0.27 % | |||
| Current Valuation | 13.72 B | |||
| Shares Outstanding | 62.97 M | |||
| Shares Owned By Insiders | 2.52 % | |||
| Shares Owned By Institutions | 93.17 % | |||
| Price To Earning | 15.29 X | |||
| Price To Book | 3.49 X | |||
| Price To Sales | 2.60 X | |||
| Revenue | 3.09 B | |||
| Gross Profit | 2.88 B | |||
| EBITDA | 718.41 M | |||
| Net Income | (329.67 M) | |||
| Cash And Equivalents | 833.95 M | |||
| Cash Per Share | 14.72 X | |||
| Total Debt | 6.02 B | |||
| Debt To Equity | 64.50 % | |||
| Current Ratio | 3.15 X | |||
| Book Value Per Share | 43.65 X | |||
| Cash Flow From Operations | 778.51 M | |||
| Earnings Per Share | (0.26) X | |||
| Price To Earnings To Growth | 3.86 X | |||
| Target Price | 208.5 | |||
| Number Of Employees | 3.2 K | |||
| Beta | 0.71 | |||
| Market Capitalization | 8.38 B | |||
| Total Asset | 12.3 B | |||
| Z Score | 0.6 | |||
| Net Asset | 12.3 B |
About Jazz Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Jazz Pharmaceuticals plc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Jazz Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Jazz Pharmaceuticals plc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Jazz Stock
When determining whether Jazz Pharmaceuticals plc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Jazz Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Jazz Pharmaceuticals Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Jazz Pharmaceuticals Plc Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Jazz Pharmaceuticals plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.